

Chairman's Message

Dear Shareholders, dear Business Partners,

We are currently going through extraordinary times. Our industry, the biopharma industry, is called upon to address the world's most pressing needs arising from the coronavirus pandemic. The level of effort, global collaboration and speed of progress on coronavirus vaccines and Covid-19 medications is unprecedented: Some of our customers went from mapping the coronavirus genome to delivering vaccines to patients in only nine months so biopharma has really demonstrated what it is able to achieve when it cooperates on a global scale and works at its best. It has also rewritten some implicit rules by which it used to operate. And I am convinced that many changes and lessons-learned are here to stay.

In this joint effort, Sartorius Stedim Biotech is part of the solution. Each and every day, we deliver essential products and technologies to manufacturers of coronavirus vaccine and medications for Covid-19 treatment all over the world – also beyond the current pandemic. With our technologies, platforms and partnerships, we help to ensure that new scientific discoveries can be translated more quickly into effective medications and that these become accessible to more people. In other words, our company's purpose directly addresses the United Nations' Sustainable Development Goal "Health and Wellbeing," placing it at the center of our efforts.

While we faced increasing pressure throughout the year to ramp up our production and serve customers with urgently required products, our first and foremost priority was to keep our employees safe at all our Group sites. We are thankful to report that we did not have any serious illnesses among our employees and that nobody acquired an infection at work. This was also due to the diligence of our Environmental Health & Safety teams who quickly provided protective materials and implemented coronavirus testing and hygiene measures at all sites. My thanks go out to these teams for their great efforts.

Businesswise, we have achieved strong results in 2020 once again, which underscore the strength and resilience of our strategy and business model. Our company grew in all its geographies, driven by strong organic development, several acquisitions and additional pandemic-related demand. Sales revenue surged by more than a third to €1,910 million, significantly surpassing our initial forecast of 11% to 14% that we issued at the beginning of the year. Underlying EBITDA, our Group's most important earnings indicator, also rose very strongly by 43.5% to €605 million. The respective margin climbed to 31.7%, and relevant net profit reached €384 million.

We are also pleased to report that we were again able to increase the number of employees significantly, to more than 7,500, a gain of more than 1,400 people. Around 240 joined us through acquisitions, and we also hired a substantial number of people particularly in manufacturing to cope with strong demand. Moreover, as a fast-growing company, we continue to recruit people who share our ambitions and values.

In addition, we were also able to complete some strategically very relevant acquisitions which, in particular, have strengthened our position in downstream processing and in the area of advanced therapies.

Efficient downstream processing has remained a challenge in our industry for years, and Sartorius Stedim Biotech is committed to helping accelerate and simplify this crucial step. Through the acquisitions of chromatography systems and the resins business from Danaher Corporation and the one of the Slovenian purification specialist BIA Separations, we significantly expanded our chromatography portfolio for essential steps in the purification of biopharmaceuticals. At the same time, we have reinforced our positioning in new



modalities, such as cell and gene therapies, which are likely to play a significant role in conquering a number of severe diseases and are currently the subject of hundreds of ongoing clinical trials. We are also pleased to welcome the WaterSep BioSeparations team to our company, experts in hollow-fiber membrane devices and pre-sterilized assemblies for biopharmaceutical applications, including novel platforms.

In early 2021, we announced that we agreed to acquire the chromatography process equipment division of Novasep. This division of approximately 100 people specializes in resin-based batch and intensified chromatography systems. The Novasep portfolio would perfectly complement our existing chromatography offering. The proposed transaction is still subject to antitrust approvals and is expected to close during the first half of 2021.

Let's take a look at how our shares performed this year, which showed high volatility on the capital markets. The positive business performance of our Group resulted in a further rise in the valuation of Sartorius Stedim Biotech shares, which reached an all-time high of €358 on June 6, 2020. Shares closed the year at €291 up 97% year over year, strongly outperforming key indices, such as the CAC 40, CAC Large 60 and MSCI Europe. With respect to dividends, the Board of Directors has decided to submit a proposal to the Annual Shareholders' Meeting on March 24, 2021, to pay out €0.68 per share.

What can we expect of 2021? The pandemic is not yet over so protecting the health of our employees continues to be our top priority. In such an environment, even short-term forecasts are subject to increased uncertainty. But we are very optimistic about our future and, from today's perspective, expect continuous strong growth for the current fiscal year and beyond. For 2021, sales revenue is forecasted to increase by about 20% to 26%. Regarding profitability, we project an underlying EBITDA margin of about 32.0%, up from 31.7% in 2020.

To support this growth, we have started to accelerate and extend the expansion of our production capacities very significantly in all geographies, the Americas, Europe, and Asia. We will also expand our presence with customers, particularly in China and the U.S., by setting up Customer Interaction Centers and investing in a very significant extension of our activities in South Korea. Therefore, our CAPEX ratio in 2021 is expected to be at a relatively high level of around 15%.

The integration of the above-mentioned acquisitions has progressed very well, and we continue to look for complementary, innovative companies that make our offering even more relevant to customers. In this context, we will also further invest in the rapidly evolving areas of tools for cell and gene therapies and next-generation biopharmaceuticals, which can significantly change the biopharma landscape in the long term. Helping customers digitize their processes and making the most of their data will also remain on our agenda, and we will continue to leverage our partnerships for sourcing further innovation.

Looking ahead to 2025, we considerably raised our mid-term targets, given the strong results we achieved in 2020 and the resulting higher relevant baseline values, as well as raised expectations regarding future organic growth potential. Accordingly, we are striving to again double sales revenue to about €4 billion in the five-year period up to 2025. We intend to achieve this increase primarily through organic growth and additional acquisitions. The Group's underlying EBITDA margin is forecasted to rise to around 33%.

We will achieve these ambitious targets only with an outstanding team. In 2020, a year that was a great challenge for all of us, both personally and professionally, the Sartorius Stedim Biotech team proved its team spirit and capabilities. We were able to successfully master the challenges thanks to the great commitment and flexibility of all our employees. In this special year, everyone went a countless number of extra miles to ensure the stability of supply chains, maintain and ramp up production, and intensively interact with customers. Therefore, a big thank you goes out to the entire international Sartorius Stedim Biotech team who did a fantastic job.

I would also like to thank you, our valued customers, business partners, and shareholders. Based on the trust you have placed in us, you have contributed significantly to the positive development of Sartorius Stedim Biotech. We would be pleased if you would continue to accompany us in 2021 and beyond and share in the future success of our company.

Sincerely,



Joachim Kreuzburg
Chairman of the Board and CEO



Board of Directors

Board of Directors

The Board of Sartorius Stedim Biotech is the central management and supervisory entity of the company, and is composed of eight members. The directors are appointed for a three-year term.



Joachim Kreuzburg
Chairman | CEO



Pascale Boissel



Chrystel Baudere



Susan Dexter



René Fáber



Anne-Marie Graffin



Lothar Kappich



Henri Riey

Sartorius Stedim Biotech Shares

Facts about the Share ¹

ISIN	FR0013154002
Liquidity provider	Gilbert Dupont
Stock exchange	Euronext Paris
Market segment	Local Securities - Compartment A (Large Caps)
Indexes	SBF 120; CAC Next 20; CAC Large 60; CAC All-Tradable; CAC All Shares; CAC Healthcare; STOXX Europe 600; MSCI France
Number of shares	92,180,190
thereof Sartorius AG	73.8%
thereof free float	26.2%
Voting rights	160,531,960
thereof Sartorius AG	84.8%
thereof free float	15.2%

¹ As of December 31, 2020

Stock Markets Impacted by Pandemic


The coronavirus pandemic and the measures taken to stem it caused global economic activity to drop sharply and company profit expectations to fall in the first quarter of 2020. Global stock markets recorded significant losses, as a result of which leading indices fell to a multi-year low in mid-March. Supported by governments' extensive economic-stimulus packages and a further loosening of monetary policy, a countermovement set in at the beginning of the second quarter that held through the end of the year. Against this backdrop, the Dow Jones reached a new all-time high, closing the reporting period up 6.0% at 30,606 points. The leading French stock index CAC 40 could not fully recover the price losses from the beginning of the year and closed at 5,551 points, down 7.1%. The SBF 120 and CAC Large 60, home to Sartorius Stedim Biotech shares, also decreased by 6.6% and 6.9% respectively.

Sartorius Stedim Biotech Shares Rise Substantially


The Sartorius Stedim Biotech share price developed positively yet again. Contributing factors included better-than-expected business performance, several upward revisions to forecasts, and the completion of three acquisitions. The share reached an all-time high of €357.6 on June 6, 2020, and closed the stock-market year somewhat lower at €291.2 – up 97.2% year over year.

In September 2020, the Sartorius Stedim Biotech share was admitted to the CAC Next 20 index and therefore also to the CAC Large 60 index. The CAC Next 20 consists of the 20 highest ranking companies that, based on a combination of their rankings on free-float-adjusted market capitalization and stock exchange turnover, are not included in the French benchmark index CAC 40.

Sartorius Stedim Biotech Share in €
January 1, 2016 to December 31, 2020



Sartorius Stedim Biotech Share in Comparison to the SBF 120 and MSCI Europe Index (indexed)
January 1, 2020 to December 31, 2020



Investor Relations Activities

Sartorius Stedim Biotech's investor relations activities follow the objective of making the current and future development of the company transparent for its stakeholders. To achieve this objective, the company maintains an ongoing, open dialog with shareholders, potential investors and financial analysts.

Besides providing quarterly, first-half and annual reports, we inform the capital market and the interested public at quarterly teleconferences and in regularly published press releases about the current development of our business and other material events at the company. Moreover, Group management and the IR team made themselves available to capital market participants at mostly virtual conferences and roadshows.

All information and publications relating to our company and its shares are provided on our website at www.sartorius.com.

Analysts

The recommendations of financial analysts serve as a foundation for the decisions of private and institutional investors when investing in shares. Currently, nine institutions regularly prepare reports and updates on Sartorius Stedim Biotech shares.

Research Coverage

Date	Institute	Price target in €	Recommendation
January 27, 2021	UBS	193.00	Sell
November 24, 2020	J.P. Morgan	351.00	Buy
October 22, 2020	Société Générale	388.00	Buy
October 20, 2020	Gilbert Dupont	275.00	Sell
October 5, 2020	Oddo BHF	293.00	Hold
September, 24, 2020	Berenberg	342.00	Buy
May 28, 2020	Morningstar	170.00	-
October 22, 2019	Intron Health	150.00	Buy
September 19, 2019	AlphaValue	121.00	Sell


Dividends

The total return generated by Sartorius Stedim Biotech shares has generally been based almost entirely on the positive development of the share price and only to a very small extent on dividend payments. In line with the rapid and highly innovation-driven development of our industry, the main focus of company's management is on successfully continuing on our dynamic profitable growth track and on making the extensive investments in capacity expansions, innovations and acquisitions that are constantly required for this purpose. Yet within this context, Sartorius Stedim Biotech strives to enable its shareholders to participate appropriately in the company's success through dividends.

The Board of Directors will submit a proposal to the Annual Shareholders' Meeting on March 24, 2021, to pay dividends of €0.68 per share from the underlying net profit of €383.8 million for fiscal 2020, up from the previous year's figure of €0.34. If this proposal is approved, the total profit distributed would be €62.7 million (2019: €31.3 million). The corresponding dividend payout ratio would be 16.3%, above the prior-year ratio of 11.9%, yet below the ratios of the years further back. The basic impacts of the coronavirus pandemic can

meanwhile be better estimated than a year ago when the original dividend proposal was reduced due to this situation, but company management is preparing for above-average macroeconomic uncertainties and risks in 2021 as well. Even more important reasons for this dividend proposal are, however, the significant rise in demand, the capacity expansion projects that are considerably more extensive in 2021 than those originally planned, and the higher investments entailed. Regarding the mid-range growth expectations also significantly raised and the investments required to achieve this expansion, the Board of Directors will use its discretion in also suggesting dividend payout ratios at about the level planned for 2020 to Annual Shareholders' Meetings to be held in the coming years.

Dividends in €



1 The original dividend proposal of €0.68 per share was adjusted in light of the pandemic crisis

2 Amount suggested by the Board of Directors and subject to approval by the Annual General Shareholders' Meeting

Total Shareholder Return


Total shareholder return considers both the dividends paid out and any share price increases over a certain period, and thus reflects the entire performance of an investment. In 2020, Sartorius Stedim Biotech shares delivered a TSR of 97.4%, up from 69.7% a year earlier.

Shareholder Structure

Sartorius Stedim Biotech S.A.'s issued capital amounted to €18.4million as of December 31, 2020, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares confer double voting rights, there were 160,531,960 voting rights in total as of the reporting date.

As of December 31, 2020, Sartorius AG has held 73.8% of the Stedim Biotech S.A.'s share capital and 84.8% of the voting rights outstanding. The remaining 26.2% of Stedim Biotech S.A. shares are in free float, corresponding to 15.2% of the voting rights outstanding.

Shareholding Structure in % of share capital



Key Figures for Sartorius Stedim Biotech Share

		2020	2019	2018	2017	2016
Share price ¹ in €	Reporting date	291.20	147.70	87.35	60.29	59.97
	High	357.60	149.20	119.80	72.49	68.84
	Low	143.00	83.30	60.35	51.50	51.17
Dividends ² in €		0.68	0.34	0.57	0.46	0.42
Total dividends paid ² in millions of €		62.7	31.3	52.5	42.4	38.7
Dividend yield ³ in %		0.2	0.2	0.7	0.8	0.7
Market capitalization in millions of €		26,842.9	13,615.0	8,051.9	5,557.5	5,528.0
Average daily trading number of shares		70,414	63,935	80,140	52,753	46,752
Trading volume of shares in millions of €		4,234.6	2,037.8	1,874.9	818.2	714.2
CAC Large 60 (closing prices of the year)		6,144	6,598	5,246	5,871	5,356
SBF 120 (closing prices of the year)		4,432	4,704	3,756	4,251	3,836

1 Daily closing price

2 For 2020, amounts suggested by the Board of Directors and subject to approval by the Annual General Shareholders' Meeting

3 Dividends in relation to the corresponding closing prices of the year

Sources: Euronext; NASDAQ